Nuvalent (NUVL) Total Liabilities (2020 - 2026)
Nuvalent (NUVL) reported Total Liabilities of $156.8 million for Q1 2026, up 65.47% on a YoY basis from $94.7 million in Q1 2025, and down 4.61% quarter-over-quarter from $164.4 million in Q4 2025.
Nuvalent (NUVL) Total Liabilities (2020 - 2026) Analysis & Trends
Nuvalent has reported Total Liabilities for 7 years, with the latest figure at $156.8 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities rose 65.47% year-over-year to $156.8 million; the trailing twelve-month figure through Mar 2026 stood at $156.8 million (up 65.47% YoY), and the FY2025 full-year result was $164.4 million, up 128.41% from the prior year.
- Total Liabilities for Q1 2026 stood at $156.8 million, down from $164.4 million in the prior quarter.
- The five-year high for Total Liabilities was $164.4 million in Q4 2025, with the low at $8.1 million in Q1 2022.
- Historically, Total Liabilities has averaged $59.5 million across 5 years, with a median of $33.4 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities slumped 78.97% — and 2025, when it surged 183.45%.
- Nuvalent's Total Liabilities stood at $19.5 million in 2022, then surged by 63.35% to $31.8 million in 2023, then surged by 126.13% to $72.0 million in 2024, then soared by 128.41% to $164.4 million in 2025, then decreased by 4.61% to $156.8 million in 2026.
- The last three Total Liabilities figures came in at $156.8 million (Q1 2026), $164.4 million (Q4 2025), and $134.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1.74 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 15.48 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 731.60 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 19.51 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 10.44 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 943,068.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 7.12 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 137.56 Mn |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | 156.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 156.78 Mn |
| Dec 31, 2025 | 164.37 Mn |
| Sep 30, 2025 | 134.51 Mn |
| Jun 30, 2025 | 100.80 Mn |
| Mar 31, 2025 | 94.75 Mn |
| Dec 31, 2024 | 71.96 Mn |
| Sep 30, 2024 | 67.73 Mn |
| Jun 30, 2024 | 38.19 Mn |
| Mar 31, 2024 | 33.43 Mn |
| Dec 31, 2023 | 31.82 Mn |
| Sep 30, 2023 | 29.10 Mn |
| Jun 30, 2023 | 20.80 Mn |
| Mar 31, 2023 | 17.02 Mn |
| Dec 31, 2022 | 19.48 Mn |
| Sep 30, 2022 | 12.98 Mn |
| Jun 30, 2022 | 10.04 Mn |
| Mar 31, 2022 | 8.12 Mn |
| Dec 31, 2021 | 8.79 Mn |
| Sep 30, 2021 | 6.84 Mn |
| Jun 30, 2021 | 5.83 Mn |